Ironwood and Allergan to co-promote Viberzi in USA

USA-based Ironwood Pharmaceuticals (Nasdaq: IRWD) has entered into an agreement for the US co-promotion of Viberzi (eluxadoline), Ireland-incorporated Allergan’s (NYSE: AGN) new treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D).

This arrangement is separate from and complementary to the companies’ ongoing co-development and co-commercialization of Linzess (linaclotide) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

“This collaboration enables Ironwood and Allergan to work together to bring forward two innovative medicines demonstrated to improve the abdominal pain and bowel dysfunction that define IBS-C and IBS-D, two types of IBS that impact nearly 30 million adult Americans,” said Bill Meury, executive vice president of commercial, North American brands for Allergan, adding: “Allergan and Ironwood have an established and successful partnership co-promoting Linzess in the US market, and we have demonstrated the strength of our combined commercial teams in accessing and educating both gastroenterologists and primary care physicians.”

Terms of the accord